PINEVILLE, N.C. (CAROLINA SPORTS LIVE) — In soccer, goalkeepers always have to be on their toes in order to prevent other teams from scoring. Having a strong one on your team usually leads to success ...

CSL has slipped to its lowest level in a decade as selling pressure weighs heavily on Australia's healthcare sector. Capital has increasingly rotated towards resource and energy companies while major ...

The ASX 200 faces a technical test near resistance, with volume confirmation, breadth and sector leadership likely to decide whether the move carries conviction. The latest market setup has brought ...

CSL Ltd (ASX: CSL) shares have not felt like a classic blue-chip winner lately. The biotechnology giant has disappointed the market, reset expectations, and left many long-term shareholders wondering ...

The price for the CSL Ltd stock decreased slightly today. Compared to yesterday there is a change of -€0.300 (-0.450%).

Amid the drama at the biotech, a new figure has stepped up right as the company needs a new long-term chief executive and chairman. Brian McNamee is CSL’s immovable object and unstoppable force. But ...

CSL shares have been hammered by earnings disappointments. But the long-term investment case remains strong. You’re reading a free article with opinions that may differ from The Motley Fool’s Premium ...

CSL does not fit neatly into the typical biotech strategy mold. While much of the industry’s attention is focused on artificial intelligence (AI) drug discovery, obesity medicines, antibody-drug ...

This article first appeared on GuruFocus. CSL Ltd. (CMXHF) suffered its sharpest share-price drop on record after the Australian biotechnology company cut its full-year outlook, warned that its ...

In a 90-day review, CSL told the market it would take another $US5bn ($A6.9bn) non-cash impairment. The first $1.5bn of this was recognised during the first-half ...

CSL has slashed its revenue projection for the fiscal year from $15.8 billion to $15.2 billion, in another indication of the Australian company’s financial distress since its ill-fated 2022 ...

CSL trades at a discount despite owning a dominant, hard-to-replicate global plasma-derived therapies infrastructure. Transformation Program targets $500–$550M in annual pre-tax cost reductions by ...